ArticleOral oncology2020
Patient-reported financial toxicity and adverse medical consequences in head and neck cancer.
Article in Oral oncology, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 44 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
44 citing papers in PubMed, 2 syntheses or guidelines pooled it, 70 citations in OpenAlex.
- Exploring the role of health-related quality of life measures in predictive modelling for oncology: a systematic review.Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation · 2025Pooled it
- Measuring financial toxicity in head and neck cancer: a systematic review.Acta otorhinolaryngologica Italica : organo ufficiale della Societa italiana di otorinolaringologia e chirurgia cervico-facciale · 2024Pooled it
- Article
- Baseline Financial Toxicity and Cost-Coping Mechanisms Among Patients Presenting for Radiation Therapy.Advances in radiation oncology · 2026Article
- Review
- Longitudinal Associations Between Financial Toxicity and Health-Related Quality of Life for Patients With Cancer.JCO oncology practice · 2026Article
- Treatment Interruption and Outcomes in Head and Neck Cancer: A Secondary Analysis of 3 Randomized Clinical Trials.JAMA otolaryngology-- head & neck surgery · 2026Article
- Differences in patient-centered burdens and economic outcomes based on sociodemographic characteristics and social determinants of health: a scoping review.Frontiers in public health · 2026Article
- Quality of Life and Return to Work After Radiotherapy in Young Adults With Head-and-Neck Cancer-A Bicentric Cross-Sectional Observational Study.Cancer medicine · 2026Observational
- Article
- Long-Term Survivor of Laryngeal Small Cell Neuroendocrine Carcinoma.The Permanente journal · 2025Article
- Implementation Mapping to Identify Strategies to Increase Timely Postoperative Radiotherapy Initiation for Head/Neck Cancer.Otolaryngology--head and neck surgery : official journal of American Academy of Otolaryngology-Head and Neck Surgery · 2025Article
- Non-monetary burdens of out-of-pocket costs incurred by patients and caregivers for medical care: a scoping review.BMJ open · 2025Article
- Review
- The impact of financial burden on quality of life among German head and neck cancer survivors.BMC cancer · 2025Article
- Article
- Assessment of the financial toxicity in patients with differentiated thyroid cancer: a cross-sectional study in western China.Frontiers in public health · 2025Article
- A Phenomenological Approach to Financial Toxicity: The-Economic-Side Effect of Cancer.Current oncology (Toronto, Ont.) · 2024Article
- Association of patient-reported financial barriers with healthcare utilization among Medicare beneficiaries with a history of cancer.Journal of cancer survivorship : research and practice · 2024Article
- Severity of Financial Toxicity for Patients Receiving Palliative Radiation Therapy.The American journal of hospice & palliative care · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
21 authors at 1 institution in 1 country.
Funding
Abstract
objectivesFinancial toxicity (FT) is a significant barrier to high-quality cancer care, and patients with head and neck cancer (HNCA) are particularly vulnerable given their need for intensive support, daily radiotherapy (RT), and management of long-term physical, functional, and psychosocial morbidities following treatment. We aim to identify predictors of FT and adverse consequences in HNCA following RT. MATERIALS AND
methodsWe performed a prospective survey study of patients with HNCA seen in follow-up at an academic comprehensive cancer center (CCC) or Veterans Affairs hospital between 05/2016 and 06/2018. Surveys included validated patient-reported functional outcomes and the COST measure, a validated instrument for measuring FT.
resultsThe response rate was 86% (n = 63). Younger age and lower median household income by county were associated with lower COST scores (i.e., worse FT) on multivariable analysis (p = .045 and p = .016, respectively). Patients with worse FT were more likely to skip clinic visits (RR (95% CI) 2.13 (1.23-3.67), p = .007), be noncompliant with recommended supplements or medications (1.24 (1.03-1.48), p = .02), and require supportive infusions (1.10 (1.02-1.20), p = .02). At the CCC, patients with worse FT were more likely to require feeding tubes (1.62 (1.14-2.31), p = .007). Overall, 36% reported that costs were higher than expected, 48% were worried about paying for treatment, and 33% reported at least a moderate financial burden from treatment.
conclusionHNCA patients experience substantial FT from their diagnosis and/or therapy, with potential implications for medical compliance, QOL, and survivorship care.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.